ASX:CU6Pharmaceuticals
Clarity Pharmaceuticals Valuation After AMPLIFY Trial Recruitment Surges Past Initial Target
Clarity Pharmaceuticals (ASX:CU6) is back in focus after announcing its Phase III AMPLIFY trial of 64Cu-SAR-bisPSMA for prostate cancer recurrence has recruited more participants than originally planned in the US and Australia.
See our latest analysis for Clarity Pharmaceuticals.
The AMPLIFY recruitment update and recent conference appearance follow a mixed earnings release and a period of strong share price momentum, with a 30 day share price return of 15.90% and a 1 year total shareholder...